The company said it will use the proceeds to repay outstanding debts including $300 million in senior notes due April 2019 and for general corporate purposes.
The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.
Opko will use the proceeds to fund R&D to further develop its diagnostics and pharmacy portfolio, and for working capital including debt repayment.
The firm will use the funds to continue its commercialization plans for the Unyvero diagnostic test cartridges and instruments.
The company said it plans to use the net proceeds for general corporate purposes, including for working capital and possible acquisitions.
The firm has made two separate senior notes offerings in euros and British pounds, and it plans to use the proceeds to redeem other outstanding notes.
The company plans to use the proceeds to repay loan and revolving credit facilities incurred to pay a portion of its 2017 acquisition of Euroimmun.
The firm has said that it intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due in 2022 in the amount of $1 billion.
Underwriter Merrill Lynch exercised in full the option to purchase up to an additional $90M in senior notes on top of a $600M notes offering announced last week.
The firm intends to use the net proceeds and available cash to redeem its outstanding 5.25 percent senior notes due 2022 in the amount of $1 billion.